2nd Annual Conference of OOTR
On November 11-12, 2005, the 2nd Annual Conference was held at
Roppongi Academy Hills in Tokyo, Japan. The theme of the conference was "Creating New Strategies for Cancer
Therapy and Prevention - From Basic Science to Clinical Science -." We provided the
participants a comprehensive program that enhances understanding of development for cancer therapy.
Dr. Stefan Gluck's Presentation
On November 10, 2005, Dr. Stefan Gluck of Miami University gave a lecture to a small
group of people at the Investigators' Meeting at the Roppongi Academy Hills. more
More than 20 internationally known cancer research scientists and cancer therapy physicians gathered to exchange their ideas and to create new strategies for cancer treatment and prevention. In the afternoon of November 12, 2005 a panel discussion entitled "Creating New Strategies for Tomorrow" took place.
The abstracts of the oral presentations
are also available by clicking the speakerr's name below.
Dr. Cao presented new aspects of molecular mechanism of tumor angiogenesis
and lymphangiogenesis, in particular, their associations, as well as the importance
of VEGF and PDGF balance.
Dr. Alaoui-Jamali presented the significance of the focal adhesion pathway in Her-2+
breast cancer progression and its importance as a therapeutic target.
Dr. Umezawa
introduced a new screening system of Anti-neoplastic agents. As an example,
he talked about a novel NF-KAPPA B inhibitor, DHMEQ, which provides anti-inflammatory,
anti-angiogenic and anti-proliferative activities in the pathway of tumor progression.
Dr. Bosslet focused on a novel oral Multi-target Tumor Growth Inhibitor which
inhibits tumor-induced angiogenesis and cell cycle progression, ZK 304709. This
compound inhibits CDKs, VEGF receptors and PDGF receptors. In animal experiments,
ZK 304709 looked extremely promising, and it is currently undergone in Phase
I Clinical trials.
Dr. Yagita talked about the most recent topics of the molecular network of circadian
clock in cancer cells and presented an implication for cancer therapy.
Dr. Dewan focused on the importance of NK cells in breast cancer progression.
He, along with his colleagues, developed a new animal experimental system with
NOD/SCID mice where the relevance of NK cell function is accessible. He also
talked about the cases which showed responses to NK cell therapy.
Dr. Gasparini summarized recent advances of novel molecular targeting therapies,
in particular, anti-VEGF therapies and anti-HER therapies. He also talked about
a new paradigm with these agents for future cancer therapies.
Dr. Rich
presented the recent improvement in biomarker research, particularly, proteomic
markers for cancer patients. He also showed future models with these modern
techniques in cancer diagnosis and cancer therapy.
Dr.
Lønning summarized the data of gene expression profiles obtained
by comprehensive analysis of the transcriptome in breast cancer. Furthermore,
he touched on his experiences of predictions of chemoresistance with markers
obtained by these researches.
Dr.
Ueno introduced novel markers to detect apoptosis and/or cell death in the
systemic circulation. According to his system, it is possible to measure the
chemotherapy-induced apoptosis and/or cell death in primary and metastatic breast
cancer.
Dr. Yiu
talked about proteomics of multidrug resistance in breast cancer. The proteomic
patterns were shown by 2-DGE and MALDI-MS or MS-MS. He also talked about preliminary
results in the treatment of human breast cancer.
Dr.
Taketo presented the mouse models of Helicobacter-induced inflammation,
its relevance to gastric tumorigenesis, and therapeutic implication. He emphasized
the importance of anti-inflammatory therapies for the chemoprevention of gastrointestinal
cancers.
Dr.
Ruschitzka focused on cardiovascular disorders caused by COX2 inhibitors
as toxicity. He comprehensively reviewed the incidents of cardiovascular disorders
in clinical trials using COX2 inhibitors for cancer diseases and non-cancer
diseases. In particular, he addressed the difference in cardiovascular incidents
and ethiology between celecoxib and rofecoxib. He also showed a new perspective
of selective COX-2 inhibitors for cancer chemoprevention.
Dr.
Sasano addressed the present situation and issues of chemoprevention
for breast cancer in Asian countries. Although the instance of breast cancer
has been rapidly increasing in Asian countries, incidents are still rather low
compared to that of the western countries. Therefore, he suggested that chemoprevention
unique to Asian countries is required.
Dr.
Lønning summarized recent advances in the endocrine therapies for
breast cancer, particularly from the point of the biomarker relevance. He also
introduced new surrogate biomarkers for endocrine therapies responsiveness.
Dr.
Kumar focused on the signaling network related to HER families. He particularly
talked about the importance of p21 activated kinases and the related pathways.
These molecules are characterized as a crucial and new therapeutic target for
cancer treatment.
Dr.
Wojtwicz summarized clinical trial data of anti-HER therapies. Anti-HER therapies
demonstrated significant anti-tumor effects against colorectal carcinoma, squamous
cell carcinoma of the head and neck, non-small cell lung cancer and renal cell
carcinoma. Both single-agent clinical trials as well as combination studies
with chemotherapy have shown the usefulness of anti-HER therapy. She also talked
about the new ways to optimize dosing and scheduling for HER-targeting drugs.
Dr.
Pegram addressed the updated results of anti-HER2 therapies and anti-VEGF
therapies. He also talked about the possibility of the combination therapy of
different types of molecular-targeting treatments. As an example, he introduced
promising results of anti-HER2 and anti-VEGF combination therapies.
Dr.
Harris firstly addressed the importance of hypoxia and hypoxia-related angiogenesis
in tumor progression. Furthermore, he introduced the cutting-edge researches
on tumor vascular biology, such as Delta-4 and Notch signaling pathway. He also
touched on pre-clinical and clinical investigations of the copper chelating
agents.
Dr. Toi
and Dr. Harris chaired the session and all the speakers participated as panelists.
They discussed the future strategy with anti-angiogenesis therapies and anti-HER
therapies. They clarified the issues of these molecular-targeting therapies
according to recent clinical trial data and further discussed how to overcome
such issues. The panel literally exemplified translational research as basic
scientists and clinical scientists discussed the essential role of the biomarker
development.
 Back
to events list
|
